According to GlaxoSmithKline's latest financial reports the company has $6.35 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | $6.35 B | -31.7% |
2022-12-31 | $9.30 B | 66.71% |
2021-12-31 | $5.58 B | -33.63% |
2020-12-31 | $8.41 B | 39.85% |
2019-12-31 | $6.01 B | 19.7% |
2018-12-31 | $5.02 B | -4.96% |
2017-12-31 | $5.28 B | -14.15% |
2016-12-31 | $6.15 B | -29.64% |
2015-12-31 | $8.75 B | 27.54% |
2014-12-31 | $6.86 B | -25.72% |
2013-12-31 | $9.23 B | 34% |
2012-12-31 | $6.89 B | -24.65% |
2011-12-31 | $9.14 B | -5.04% |
2010-12-31 | $9.63 B | -14.24% |
2009-12-31 | $11.23 B | 11.57% |
2008-12-31 | $10.06 B | 11.72% |
2007-12-31 | $9.01 B | 50.99% |
2006-12-31 | $5.96 B | -33.65% |
2005-12-31 | $8.99 B | 17.81% |
2004-12-31 | $7.63 B | 23.7% |
2003-12-31 | $6.17 B | 100.36% |
2002-12-31 | $3.08 B | 6.36% |
2001-12-31 | $2.89 B |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Novartis NVS | $13.96 B | 119.71% | ๐จ๐ญ Switzerland |
Pfizer PFE | $12.69 B | 99.69% | ๐บ๐ธ USA |
Sanofi SNY | $9.92 B | 56.23% | ๐ซ๐ท France |
Merck MRK | $7.09 B | 11.62% | ๐บ๐ธ USA |
AstraZeneca AZN | $5.86 B | -7.79% | ๐ฌ๐ง UK |
Teva Pharmaceutical Industries TEVA | $3.22 B | -49.24% | ๐ฎ๐ฑ Israel |
Dynavax Technologies
DVAX | $0.74 B | -88.32% | ๐บ๐ธ USA |